A5047869667- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Circular RNAs in diseases
- Acute Myeloid Leukemia Research
- Lung Cancer Treatments and Mutations
- Multiple Myeloma Research and Treatments
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Sarcoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Immune Cell Function and Interaction
- Autoimmune and Inflammatory Disorders Research
- Neuroblastoma Research and Treatments
- Cancer-related molecular mechanisms research
- Cancer-related Molecular Pathways
- RNA Research and Splicing
- MicroRNA in disease regulation
Genmab (Denmark)
2022-2024
Rigshospitalet
2016-2024
Genmab (United States)
2024
University of Copenhagen
2018-2023
Copenhagen University Hospital
2015-2022
Business Innovation Centre
2020
Aarhus University Hospital
2015
Aarhus University
2009-2011
In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy autologous stem cell transplantation. One such strategy is Nordic MCL2 regimen, developed Group. We here present 15-year updated results study after a median follow-up 11·4 years: For all patients on an intent-to-treat basis, overall progression-free survival was 12·7 8·5 years,...
In recent years, the outcome of mantle cell lymphoma (MCL) has improved, especially in younger patients, receiving cytarabine-containing chemoimmunotherapy and autologous stem transplantation. Nevertheless, a proportion MCL patients still experience early failure. To identify biomarkers anticipating failure intensive chemotherapy MCL, we performed target resequencing DNA profiling purified tumor samples collected from enrolled prospective FIL-MCL0208 phase 3 trial (high-dose followed by...
The main objectives of the present study were to monitor minimal residual disease (MRD) in bone marrow patients with mantle cell lymphoma (MCL) predict clinical relapse and guide preemptive treatment rituximab. Among enrolled 2 prospective trials by Nordic Lymphoma Group, 183 who had completed autologous stem transplantation (ASCT) whom an MRD marker been obtained included our analysis. Fresh samples analyzed for a combined standard nested quantitative real-time PCR assay...
Summary Survival for patients diagnosed with mantle cell lymphoma (MCL) has improved drastically in recent years. However, carrying mutations tumour protein p53 ( TP53 ) do not benefit from modern chemotherapy‐based treatments and have poor prognosis. Thus, there is a clinical need to identify missense through routine analysis enable patient stratification. Sequencing widely implemented practice MCL, immunohistochemistry (IHC) feasible alternative high‐risk patients. The aim of the present...
Objectives: Epcoritamab is a novel bispecific antibody that targets CD3 and CD20 induces T-cell-mediated cytotoxic activity against CD20+ B cells, including malignant cells (2). Cytokine release syndrome (CRS) an adverse event of special interest for T cell engagers such as Epcoritamab. Step-up dosing (SUD) regimens have been investigated optimized to minimize risk CRS in EPCORE NHL-1 (NCT03625037). In addition, prophylactic corticosteroids were employed moderate adaptive innate immune hence...
Mantle cell lymphoma (MCL) is an incurable disease with a highly variable clinical course. The prognosis after relapse generally poor, and no standard of care exists. We investigated the postrelapse outcomes 149 patients who were initially treated in Nordic Lymphoma Group trials, MCL2 or MCL3, both representing intensive cytarabine-containing frontline regimens including autologous stem transplant. Patients progression before 24 months (POD24, n = 51, 34%) displayed median overall survival...
The immunomodulatory drug thalidomide, and its analogs, lenalidomide, pomalidomide (IMiDs), have become essential components of the standard treatment for multiple myeloma (MM), led to significant improvement survival in patients with this devastating disease. Cereblon (CRBN), direct target IMiDs, has been proposed as a predictive biomarker response IMiDs. Using immunohistochemistry formalin-fixed paraffin embedded (FFPE) bone marrow samples 23 treated lenalidomide-containing regimen, we...
7039 Background: Epcoritamab induces high complete response (CR) and MRD-negativity rates with manageable safety in patients (pts) challenging-to-treat R/R LBCL as shown the pivotal phase 2 study (NCT03625037). Here we present long-term data, an additional efficacy analysis from expansion cohort, data cycle 1 optimization (C1 OPT) part. Methods: Adults CD20 + ≥2 prior systemic therapies received subcutaneous epcoritamab (2 step-up doses, then 48-mg full doses per label) 28-d Cs. The primary...
The transcription factor MYC is a well-described oncogene with an important role in lymphomagenesis, but its significance for clinical outcome mantle cell lymphoma (MCL) remains to be determined. We performed investigation of the expression protein cohort 251 MCL patients complemented by analyses structural aberrations and mRNA, sub-cohort patients. Fourteen percent (n=35) showed high >20% positive cells (MYChigh), among whom only one translocation was identified, 86% (n=216) low expression....
Human cytomegalovirus (HCMV) manipulates the host immune system in various ways. Allegedly, HCMV infection is associated with increased percentages of a particular natural killer (NK) cell subset expressing activating receptor CD94/NKG2C both healthy individuals and patients infected human immunodeficiency virus (HIV). Whether HCMV-mediated induction this specific NK also apparent for other diseases characterized by abnormal responses, such as malignant blood diseases, unknown. By comparing...
AbstractAbstractMantle cell lymphoma (MCL) is a biologically and clinically heterogeneous disease, emphasizing the need for prognostic biomarkers. In this study we aimed at comparing value of two RNA-based risk scores, circSCORE MCL35, in 149 patients from MCL2 (ISRCTN87866680) MCL3 (NCT00514475) patient cohorts. Both scores provided significant stratification high versus low progression free survival (PFS) overall (OS). The retained adjusted multivariable Cox regressions PFS, but not OS....